bird-flu-stocks-logo
birdflustocks.com
SAB Biotherapeutics: SAB-176 Phase 2a study completed, FDA has granted Fast Track designation
birdflustocks.com » bird flu stocks  »  SAB Biotherapeutics: SAB-176 Phase 2a study completed, FDA has granted Fast Track designation
SAB Biotherapeutics: SAB-176 Phase 2a study completed, FDA has granted Fast Track designation
April 13, 2023

https://ir.sab.bio/news-releases/news-release-details/sab-biotherapeutics-granted-fast-track-designation-fda-sab-176